CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

Published:2019 Issue:6 Volume:4 Page:e000565
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Awada Ahmad,Gligorov Joseph,Jerusalem Guy,Preusser Matthias^ORCID,Singer Christian,Zielinski Christoph

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med Overseas Ed,2016

2. Ribociclib as first-line therapy for HR-positive, advanced breast cancer;Hortobagyi;N Engl J Med Overseas Ed,2016

3. Monarch 3: Abemaciclib as initial therapy for advanced breast cancer;Goetz;JCO,2017

4. Cdk4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion;Preusser;ESMO Open,2018

5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial;Tripathy;Lancet Oncol,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study;BMC Cancer;2024-07-30

2. Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study;Cancers;2024-05-01

3. Aberrant cytoplasmic localization of MLH1 characterizes a sub-clonal breast cancer cell population that seeds recurrence;2024-03-02

4. Total Lesion Glycolysis Levels as Predictive Indicators in Patients With Metastatic and Recurrent Breast Cancer Undergoing Endocrine Therapy With or Without CDK4/6 Inhibitor;Anticancer Research;2022-10

5. The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC;Clinical Breast Cancer;2021-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3